Research News and Research

RSS

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

State abortion bills keep coming

Some call such legislation an "overreach," but at least some of the proposals are getting political traction, including a push in Washington State this week to require insurance plans to cover abortion.

12 Mar 2012

ESMO welcomes EC proposal to streamline access to medicines

The European Society for Medical Oncology (ESMO) welcomes the recent proposal by the European Commission aimed at streamlining the process and shortening the timeline surrounding national decisions on pricing drugs and reimbursement of payment made for medicines. This initiative, says ESMO, will facilitate patient access to innovative treatments on an EU-wide level.

12 Mar 2012

LensAR closes $24 million private financing

LensAR Inc., a developer of the next generation of laser systems for cataract surgery, announced the closing of a $24 million private financing which included investments from Aisling Capital and Florida Growth Fund (FGF).

12 Mar 2012

Political cartoon: 'Aerodynamic Drag'

Kaiser Health News provides a fresh take on health policy developments with "Aerodynamic Drag" by Lisa Benson.

12 Mar 2012

AB SCIEX announces commercial expansion in Brazil

AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

Thermo Fisher Scientific introduces new ICP-MS system, iCAP Q

Thermo Fisher Scientific Inc., the world leader in serving science, today launched its new Thermo Scientific iCAP Q, an ICP-MS system that features world-class performance and increased throughput to help laboratories cut analysis times by up to 50 percent when compared to the XSERIES 2 ICP-MS, the model it replaces.

From Thermo Fisher Scientific Inc. 12 Mar 2012

Zynex announces acquisition of NeuroDyne Medical

Zynex, Inc., a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the acquisition of substantially all the assets of NeuroDyne Medical, Corp., through its subsidiary Zynex NeuroDiagnostics, Inc., with an effective date of March 9, 2012.

12 Mar 2012

Connect during MS Awareness Week

Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Therefore, it's only fitting that connections would be its greatest enemy.

12 Mar 2012

First Edition: March 12, 2012

Today's health policy headlines focus significant attention on key issues, dynamics and even personalities that will be in play when the Supreme Court takes up the health law later this month.

12 Mar 2012

Two scientists receive The Brain Prize 2012 for pioneering work on hearing and deafness

The Grete Lundbeck European Brain Research Foundation announced today that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel.

12 Mar 2012

Botulinum toxin effective in treating OAB among women

The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect up to 20% of people over the age of 40.

12 Mar 2012

ShangPharma fourth quarter net revenues increase 19.0% to $30.5 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2011.

12 Mar 2012

U-M to research into treatment for hepatitis C

The Greenview Foundation has announced a gift of $57,000 to the University of Michigan Health System to support research on a treatment for hepatitis C.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012

Sweco, ÅF sign joint contract with Skanska Healthcare for NKS in Solna

The engineering consultancies Sweco and ÅF have signed a joint contract with Skanska Healthcare AB for planning and design of the New Karolinska Hospital in Solna, NKS.

12 Mar 2012

Top-line results from Inviragen's INV21 Phase 1 trial on HFMD

Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.

12 Mar 2012

Gastrointestinal progenitor cells could be coaxed into making insulin

A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant. Until now, stem cell transplants have been seen by many researchers as the ideal way to replace cells lost in type I diabetes and to free patients from insulin injections.

12 Mar 2012